Bay­er buys a biotech ‘race horse’ with a $4B deal — $2B in cash — aimed at go­ing big in­to gene ther­a­py

In the lat­est sign that Big Phar­ma wants a lead­ing place in the push to de­vel­op a new gen­er­a­tion of cell and gene ther­a­pies, Bay­er is step­ping up to­day with a $2 bil­lion cash deal to buy out one of the fast-mov­ing pi­o­neers in the field, while adding up to $2 bil­lion more in mile­stones if the new phar­ma sub­sidiary can de­liv­er the goods.

As part of a con­tin­u­ing se­ries of deals en­gi­neered by Bay­er BD chief Mar­i­anne De Backer, the phar­ma play­er has snapped up Askle­pios, more com­mon­ly re­ferred to in more ca­su­al fash­ion as AskBio. And they are pay­ing top dol­lar for a Re­search Tri­an­gle Park-based com­pa­ny that raised $225 mil­lion a lit­tle more than a year ago to back the brain­child of Jude Samul­s­ki, the gene ther­a­py pi­o­neer out of the Uni­ver­si­ty of North Car­oli­na Gene Ther­a­py Cen­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER